Advertisement

Botulinum Toxin in Abdominal Wall Hernia Repair

  • Talar TejirianEmail author
  • Louise Yeung
Chapter

Abstract

As surgeons are treating more complex hernias, adjuncts to aid in repair can be useful in certain situations. Botulinum toxin A (BTA) is one such adjunct that can help increase intraabdominal volume and increase ease of repair for large hernias, including those with loss of domain. The evidence for the use of BTA is increasing and thus far some benefit is seen, with minimal risk. In this chapter, we will be reviewing current evidence for the use of BTA for hernia repair, and describing our technique of administration.

Keywords

Abdominal wall hernia repair Botulinum neurotoxin Hernia surgery 

References

  1. 1.
    Jankovic J. Botulinum toxin: state of the art. Mov Disord. 2017;32(8):1131–8.CrossRefGoogle Scholar
  2. 2.
    Dressler D. Clinical applications of botulinum toxin. Curr Opin Microbiol. 2012;15(3):325–36.CrossRefGoogle Scholar
  3. 3.
    Dressler D, Bigalke H. Immunological aspects of botulinum toxin therapy. Expert Rev Neurother. 2017;17(5):487–94.CrossRefGoogle Scholar
  4. 4.
    Sethi KD, Rodriguez R, Olayinka B. Satisfaction with botulinum toxin treatment: a cross-sectional survey of patients with cervical dystonia. J Med Econ. 2012;15(3):419–23.CrossRefGoogle Scholar
  5. 5.
    Evidente VG, Truong D, Jankovic J, Comella CL, Grafe S, Hanschmann A. IncobotulinumtoxinA (Xeomin®) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated. J Neurol Sci. 2014;346(1–2):116–20.CrossRefGoogle Scholar
  6. 6.
    Ramirez-Castaneda J, Jankovic J, Comella C, Dashtipour K, Fernandez HH, Mari Z. Diffusion, spread, and migration of botulinum toxin. Mov Disord. 2013;28(13):1775–83.CrossRefGoogle Scholar
  7. 7.
    Erbguth F, Claus D, Engelhardt A, Dressler D. Systemic effect of local botulinum toxin injections unmasks subclinical Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry. 1993;56(11):1235–6.CrossRefGoogle Scholar
  8. 8.
    Diener MK, Voss S, Jensen K, Büchler MW, Seiler CM. Elective midline laparotomy closure: the INLINE systematic review and meta-analysis. Ann Surg. 2010;251(5):843–56.CrossRefGoogle Scholar
  9. 9.
    Deerenberg EB, Timmermans L, Hogerzeil DP, et al. A systematic review of the surgical treatment of large incisional hernia. Hernia. 2015;19(1):89–101.CrossRefGoogle Scholar
  10. 10.
    Fink C, Baumann P, Wente MN, et al. Incisional hernia rate 3 years after midline laparotomy. Br J Surg. 2014;101(2):51–4.CrossRefGoogle Scholar
  11. 11.
    Elstner KE, Jacombs AS, Read JW, et al. Laparoscopic repair of complex ventral hernia facilitated by pre-operative chemical component relaxation using botulinum toxin A. Hernia. 2016;20(2):209–19.CrossRefGoogle Scholar
  12. 12.
    Flum DR, Horvath K, Koepsell T. Have outcomes of incisional hernia repair improved with time? A population-based analysis. Ann Surg. 2003;237(1):129–35.CrossRefGoogle Scholar
  13. 13.
    Novitsky YW. Hernia surgery: current principles. Cham: Springer; 2016.CrossRefGoogle Scholar
  14. 14.
    Novitsky YW, Elliott HL, Orenstein SB, Rosen MJ. Transversus abdominis muscle release: a novel approach to posterior component separation during complex abdominal wall reconstruction. Am J Surg. 2012;204(5):709–16.CrossRefGoogle Scholar
  15. 15.
    Caldironi MW, Romano M, Bozza F, et al. Progressive pneumoperitoneum in the management of giant incisional hernias: a study of 41 patients. Br J Surg. 1990;77(3):306–7.CrossRefGoogle Scholar
  16. 16.
    Dumont F, Fuks D, Verhaeghe P, et al. Progressive pneumoperitoneum increases the length of abdominal muscles. Hernia. 2009;13(2):183–7.CrossRefGoogle Scholar
  17. 17.
    Admire AA, Dolich MO, Sisley AC, Samimi KJ. Massive ventral hernias: role of tissue expansion in abdominal wall restoration following abdominal compartment syndrome. Am Surg. 2002;68(5):491–6.PubMedGoogle Scholar
  18. 18.
    Ibarra-Hurtado TR, Nuño-Guzmán CM, Echeagaray-Herrera JE, Robles-Vélez E, de Jesús González-Jaime J. Use of botulinum toxin type a before abdominal wall hernia reconstruction. World J Surg. 2009;33(12):2553–6.CrossRefGoogle Scholar
  19. 19.
    Jankovic J. Botulinum toxin: therapeutic clinical practice and science. Philadelphia, PA: Saunders/Elsevier; 2009.Google Scholar
  20. 20.
    Cakmak M, Caglayan F, Somuncu S, et al. Effect of paralysis of the abdominal wall muscles by botulinum A toxin to intraabdominal pressure: an experimental study. J Pediatr Surg. 2006;41(4):821–5.CrossRefGoogle Scholar
  21. 21.
    Elstner KE, Read JW, Rodriguez-Acevedo O, et al. Preoperative chemical component relaxation using Botulinum toxin A: enabling laparoscopic repair of complex ventral hernia. Surg Endosc. 2017;31(2):761–8.CrossRefGoogle Scholar
  22. 22.
    Elstner KE, Read JW, Rodriguez-Acevedo O, Ho-Shon K, Magnussen J, Ibrahim N. Preoperative progressive pneumoperitoneum complementing chemical component relaxation in complex ventral hernia repair. Surg Endosc. 2017;31(4):1914–22.CrossRefGoogle Scholar
  23. 23.
    Rodriguez-Acevedo O, Elstner KE, Jacombs ASW, et al. Preoperative Botulinum toxin A enabling defect closure and laparoscopic repair of complex ventral hernia. Surg Endosc. 2017;32(2):831–9.CrossRefGoogle Scholar
  24. 24.
    Ibarra-Hurtado TR, Nuño-Guzmán CM, Miranda-Díaz AG, Troyo-Sanromán R, Navarro-Ibarra R, Bravo-Cuéllar L. Effect of botulinum toxin type A in lateral abdominal wall muscles thickness and length of patients with midline incisional hernia secondary to open abdomen management. Hernia. 2014;18(5):647–52.CrossRefGoogle Scholar
  25. 25.
    Bueno-Lledó J, Torregrosa A, Ballester N, et al. Preoperative progressive pneumoperitoneum and botulinum toxin type A in patients with large incisional hernia. Hernia. 2017;21(2):233–43.CrossRefGoogle Scholar
  26. 26.
    Zendejas B, Khasawneh MA, Srvantstyan B, Jenkins DH, Schiller HJ, Zielinski MD. Outcomes of chemical component paralysis using botulinum toxin for incisional hernia repairs. World J Surg. 2013;37(12):2830–7.CrossRefGoogle Scholar
  27. 27.
    Zielinski MD, Kuntz M, Zhang X, et al. Botulinum toxin A-induced paralysis of the lateral abdominal wall after damage-control laparotomy: a multi-institutional, prospective, randomized, placebo-controlled pilot study. J Trauma Acute Care Surg. 2016;80(2):237–42.CrossRefGoogle Scholar
  28. 28.
    Brown SH, McGill SM. Transmission of muscularly generated force and stiffness between layers of the rat abdominal wall. Spine (Phila Pa 1976). 2009;34(2):E70–5.CrossRefGoogle Scholar
  29. 29.
    Durham PL, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache. 2004;44(1):35–42; discussion 42–33.CrossRefGoogle Scholar
  30. 30.
    Göbel H, Heinze A, Reichel G, Hefter H, Benecke R, Dysport myofascial pain study group. Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport) for the relief of upper back myofascial pain syndrome: results from a randomized double-blind placebo-controlled multicentre study. Pain. 2006;125(1–2):82–8.CrossRefGoogle Scholar
  31. 31.
    Childers MK, Wilson DJ, Gnatz SM, Conway RR, Sherman AK. Botulinum toxin type A use in piriformis muscle syndrome: a pilot study. Am J Phys Med Rehabil. 2002;81(10):751–9.CrossRefGoogle Scholar
  32. 32.
    Perez D, Wildi S, Demartines N, Bramkamp M, Koehler C, Clavien PA. Prospective evaluation of vacuum-assisted closure in abdominal compartment syndrome and severe abdominal sepsis. J Am Coll Surg. 2007;205(4):586–92.CrossRefGoogle Scholar
  33. 33.
    Smoot D, Zielinski M, Jenkins D, Schiller H. Botox A injection for pain after laparoscopic ventral hernia: a case report. Pain Med. 2011;12(7):1121–3.CrossRefGoogle Scholar
  34. 34.
    Weum S, de Weerd L. Perforator-guided drug injection in the treatment of abdominal wall pain. Pain Med. 2016;17(7):1229–32.CrossRefGoogle Scholar
  35. 35.
    Dressler D, Adib Saberi F, Bigalke H. IncobotulinumtoxinA (Xeomin(®)) can produce antibody-induced therapy failure in a patient pretreated with abobotulinumtoxinA (Dysport(®)). J Neural Transm (Vienna). 2014;121(7):769–71.CrossRefGoogle Scholar

Copyright information

© Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) 2019

Authors and Affiliations

  1. 1.Department of SurgeryKaiser Permanente Los Angeles Medical CenterLos AngelesUSA

Personalised recommendations